Literature DB >> 12491122

[Pharmacotherapy of rheumatoid arthritis].

E Gromnica-Ihle1.   

Abstract

The therapeutic goals in rheumatoid arthritis have been so far pain reduction, improvement of function and inhibition of disease progression. Nowadays therapeutic strategies must aim at the induction of remission. Long-term results clearly improve with an early start of DMARD therapy. Additional corticosteroid therapy can further reduce joint destruction. After an early start with DMARD therapy (methotrexate in most cases) corticosteroids should be additionally given in moderate and severe cases. Reconsideration of the therapeutic regime should be performed no later than three months after start of therapy. In the case of remission corticosteroids should be reduced. If there is no remission the DMARD therapy should be intensified, if necessary together with a combination therapy. After another three months a step-down concept can be applied if remission occurs. Otherwise therapy should again be intensified, if necessesary with the use of biologicals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12491122     DOI: 10.1007/s00393-002-1209-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  3 in total

1.  [Recommendations on the use of rituximab for patients with rheumatoid arthritis].

Authors:  A Rubbert-Roth; G Burmester
Journal:  Z Rheumatol       Date:  2008-11       Impact factor: 1.372

2.  [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Authors:  J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

3.  Subcellular localization and distribution of the reduced folate carrier in normal rat tissues.

Authors:  M Hinken; S Halwachs; C Kneuer; W Honscha
Journal:  Eur J Histochem       Date:  2011-01-27       Impact factor: 3.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.